Xilio Therapeutics financials
$8.94−1.24%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $43.8M | $6.3M | $0.00 | $0.00 | — |
| Gross profit | $43.8M | $6.3M | $0.00 | $0.00 | — |
| Gross margin | 100.0% | 100.0% | — | — | — |
| Operating income | -$42.0M | -$60.6M | -$79.1M | -$89.1M | -$75.0M |
| Net income | -$35.0M | -$58.2M | -$76.4M | -$88.2M | -$75.8M |
| Net margin | −80.1% | −918.0% | — | — | — |
| Diluted EPS | $-4.19 | $-15.24 | $-38.92 | $-45.08 | $-189.28 |
| EBITDA | -$40.4M | -$58.0M | -$77.2M | -$87.3M | -$73.5M |
| Operating cash flow | -$5.0M | -$18.4M | -$68.6M | -$75.7M | -$80.8M |
| Free cash flow | -$5.5M | -$18.4M | -$69.1M | -$77.6M | -$81.9M |
| Diluted shares | 8.4M | 3.8M | 2.0M | 2.0M | 0.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $137.5M | $55.3M | $44.7M | $120.4M | $198.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $3.3M | $9.8M | $9.6M |
| Total assets | $154.7M | $71.1M | $60.9M | $139.2M | $218.1M |
| Total liabilities | $119.4M | $53.5M | $24.1M | $33.5M | $32.6M |
| Shareholders' equity | $35.3M | $17.6M | $36.8M | $105.6M | $185.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology